Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNotes PayablesPayablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Quantum Genesis AI (QTZM) Cash & Equivalents (2016 - 2026)

Quantumzyme's Cash & Equivalents history spans 7 years, with the latest figure at $59.0 for Q1 2026.

  • For Q1 2026, Cash & Equivalents changed N/A year-over-year to $59.0; the TTM value through Jan 2026 reached $59.0, changed N/A, while the annual FY2025 figure was $584.0, N/A changed from the prior year.
  • Cash & Equivalents reached $59.0 in Q1 2026 per QTZM's latest filing, down from $184.0 in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $5068.0 in Q4 2024 to a low of $59.0 in Q1 2026.
  • Average Cash & Equivalents over 3 years is $1295.8, with a median of $584.0 recorded in 2025.
  • The largest YoY upside for Cash & Equivalents was 96.37% in 2025 against a maximum downside of 96.37% in 2025.
  • A 3-year view of Cash & Equivalents shows it stood at $5068.0 in 2024, then crashed by 96.37% to $184.0 in 2025, then tumbled by 67.93% to $59.0 in 2026.
  • Per Business Quant, the three most recent readings for QTZM's Cash & Equivalents are $59.0 (Q1 2026), $184.0 (Q4 2025), and $584.0 (Q3 2025).